1. Scrip
  2. >>New Products

Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars

 
• By Jessica Merrill

The company will not commercialize an insulin glargine copy already tentatively approved by FDA as Lusduna, but says it remains committed to biosimilars in oncology and immunology.

Insulin ampoule and a syringe isolated against white background

Merck & Co. Inc. has decided that it will not commercialize its own version of Sanofi's Lantus (insulin glargine) in the US, even though the product was already tentatively approved by the US FDA in 2017.

"After a comprehensive assessment of the current and future market environment for insulin glargine, which included an assessment of anticipated pricing and cost of production, we made the business decision to terminate our agreement on the commercialization of Lusduna pen and vial," Merck said in a statement to Scrip

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.